Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT06440096 |
Other study ID # |
YÖMAVD |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
March 30, 2023 |
Est. completion date |
January 5, 2024 |
Study information
Verified date |
May 2024 |
Source |
Sanliurfa Mehmet Akif Inan Education and Research Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Some indicators generated from hemogram such as neutrophil/lymphocyte (NLR) have been
suggested as biomarkers of systemic inflammation. Type I Modic changes (MCs) have
inflammatory nature histologically and are more painful clinically than type II MCs.
Therefore, we hypothesized that patients with type I MCs may have increased inflammatory
biomarkers and low back pain than those with type II MCs. The aim of this study was to test
this hypothesis.
Description:
Patients and Methods: A total of 48 patients with MCs (type I/type II=24/24) were included in
this study. Their demographic, clinical and hematologic characteristics were recorded. A 10
cm Visual Analog Scale (VAS) was used to detect low back pain intensity. Systemic
inflammatory biomarkers including NLR, monocyte/lymphocyte (MLR), platelet/lymphocyte (PLR),
neutrophil/lymphocyte*platelet (NLPR), systemic inflammatory index (SII), systemic
inflammatory response index (SIRI), and aggregate index of systemic inflammation (AISI) were
derived from whole blood cell count.
Keywords: Neutrophil-to-lymphocyte ratio, inflammation, Modic changes, back pain.